Should I buy or sell biote stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for biote in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTMD shares. View BTMD analyst ratings or view top-rated stocks .

What is biote's stock price target for 2024?

5 brokers have issued twelve-month price targets for biote's stock. Their BTMD share price targets range from $6.55 to $9.00. On average, they expect the company's share price to reach $8.11 in the next year. This suggests a possible upside of 46.4% from the stock's current price. View analysts price targets for BTMD or view top-rated stocks among Wall Street analysts .

How have BTMD shares performed in 2024?

biote's stock was trading at $4.94 at the start of the year. Since then, BTMD stock has increased by 12.1% and is now trading at $5.54. View the best growth stocks for 2024 here .

Are investors shorting biote?

biote saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 878,200 shares, an increase of 16.4% from the March 15th total of 754,400 shares. Based on an average daily trading volume, of 117,500 shares, the short-interest ratio is presently 7.5 days. Currently, 2.6% of the shares of the company are short sold. View biote's Short Interest .

When is biote's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BTMD earnings forecast .

How were biote's earnings last quarter?

biote Corp. (NASDAQ:BTMD) released its quarterly earnings data on Tuesday, March, 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.06. The business had revenue of $45.70 million for the quarter, compared to analyst estimates of $45.50 million. biote had a negative trailing twelve-month return on equity of 45.10% and a net margin of 1.79%.

What guidance has biote issued on next quarter's earnings?

biote updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million.

Who are biote's major shareholders?

biote's stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (0.90%). Insiders that own company stock include Mary Elizabeth Conlon, Roystone Capital Management Lp and Samar Jagat Kamdar. View institutional ownership trends .

How do I buy shares of biote?

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:BTMD

biote (BTMD) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BTMD Stock Alerts

$5.54

+0.10 (+1.84%)

(As of 04/19/2024 ET)

Compare

Today's Range: $5.40
▼
$5.61
50-Day Range: $4.20
▼
$6.91
52-Week Range: $3.65
▼
$8.22

Volume: 88,116 shs
Average Volume: 109,307 shs
Market Capitalization: $412.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.11

Get biote alerts:

biote MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 46.4% Upside
$8.11 Price Target
Short Interest: Bearish
2.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 53.85%
From $0.39 to $0.60 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

Medical Sector

444th out of 911 stocks

Medicinals & Botanicals Industry

3rd out of 8 stocks

3.5

Analyst's Opinion

Consensus Rating
biote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
biote has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.64% of the float of biote has been sold short.
Short Interest Ratio / Days to Cover
biote has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in biote has recently increased by 16.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
biote does not currently pay a dividend.
Dividend Growth
biote does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BTMD.

2.7

News and Social Media Coverage

News Sentiment
biote has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for biote this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, biote insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.60% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.68% of the stock of biote is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for biote are expected to grow by 53.85% in the coming year, from $0.39 to $0.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of biote is -25.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of biote is -25.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About biote Stock (NASDAQ:BTMD)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

BTMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BTMD Stock News Headlines

March 25, 2024 | msn.com

Esperion stock jumps 18% in wake of FDA label expansions

March 18, 2024 | markets.businessinsider.com

Pharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial Prospects

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

March 14, 2024 | marketwatch.com

Biote Soars 22% With Expected Acceleration in 2H 2024 Sales

March 13, 2024 | finance.yahoo.com

biote Corp. (PNK:BTMD) Q4 2023 Earnings Call Transcript

March 12, 2024 | finance.yahoo.com

Biote Corp (BTMD) Reports Growth Amidst Challenges in Q4 and Full Year 2023

March 12, 2024 | businesswire.com

Biote Reports Fourth Quarter and Full Year 2023 Financial Results

March 11, 2024 | benzinga.com

Preview: Biote's Earnings

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 27, 2024 | finance.yahoo.com

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

February 27, 2024 | businesswire.com

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

February 20, 2024 | msn.com

Biote announces agreement to resolve litigation with founder Gary Donovitz

February 20, 2024 | finance.yahoo.com

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares

February 20, 2024 | businesswire.com

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares

January 25, 2024 | finance.yahoo.com

Biote Announces $20 Million Share Repurchase Authorization

January 20, 2024 | benzinga.com

Biote Stock (NASDAQ:BTMD), Analyst Ratings, Price Targets, Predictions

January 18, 2024 | bizjournals.com

Birmingham manufacturer to be acquired for $8.5M

January 18, 2024 | realmoney.thestreet.com

Biote price target lowered by $1 at Truist, here's why

January 11, 2024 | msn.com

Biote names Robert Peterson as its CFO

January 11, 2024 | markets.businessinsider.com

Biote Names Robert Peterson CFO

January 11, 2024 | finance.yahoo.com

Biote Names Robert Peterson as Chief Financial Officer

November 30, 2023 | seekingalpha.com

biote Should Keep Delivering Strong Growth

November 8, 2023 | msn.com

Durect, Lumos Pharma among healthcare movers

November 8, 2023 | msn.com

BIOTE GAAP EPS of $0.24, revenue of $45.6M

November 8, 2023 | finance.yahoo.com

Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates

November 7, 2023 | finance.yahoo.com

Biote Reports Third Quarter 2023 Financial Results

November 5, 2023 | morningstar.com

Biote Corp BTMD

See More Headlines

Receive BTMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medicinals & botanicals
Sub-Industry: N/A
Current Symbol: NASDAQ:BTMD
CUSIP: N/A
CIK: 1819253
Web: biote.com
Phone: 844-604-1246
Fax: 212-616-9601
Employees: 194
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.11
High Stock Price Target: $9.00
Low Stock Price Target: $6.55
Potential Upside/Downside: +46.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 14.21
P/E Growth: N/A
Net Income: $3.32 million
Net Margins: 1.79%
Pretax Margin: -0.07%
Return on Equity: -45.10%
Return on Assets: 19.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.51
Quick Ratio: 4.73

Sales & Book Value

Annual Sales: $185.36 million
Price / Sales: 2.23
Cash Flow: $0.51 per share
Price / Cash Flow: 10.93
Book Value: ($0.58) per share
Price / Book: -9.55

Miscellaneous

Outstanding Shares: 74,530,000
Free Float: 62,160,000
Market Cap: $412.90 million
Optionable: Not Optionable
Beta: 0.87

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Marc D. Beer (Age 59)
Executive Chairman
Comp: $470.18k
Ms. Teresa S. Weber (Age 71)
CEO & Director
Comp: $1.06M
Ms. Mary Elizabeth Conlon (Age 43)
VP of Business Development, General Counsel & Corporate Secretary
Comp: $552.36k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTMD Stock Analysis - Frequently Asked Questions

Should I buy or sell biote stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for biote in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTMD shares.
View BTMD analyst ratings or view top-rated stocks.
What is biote's stock price target for 2024?: 5 brokers have issued twelve-month price targets for biote's stock. Their BTMD share price targets range from $6.55 to $9.00. On average, they expect the company's share price to reach $8.11 in the next year. This suggests a possible upside of 46.4% from the stock's current price.
View analysts price targets for BTMD or view top-rated stocks among Wall Street analysts.
How have BTMD shares performed in 2024?: biote's stock was trading at $4.94 at the start of the year. Since then, BTMD stock has increased by 12.1% and is now trading at $5.54.
View the best growth stocks for 2024 here.
Are investors shorting biote?: biote saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 878,200 shares, an increase of 16.4% from the March 15th total of 754,400 shares. Based on an average daily trading volume, of 117,500 shares, the short-interest ratio is presently 7.5 days. Currently, 2.6% of the shares of the company are short sold.
View biote's Short Interest.
When is biote's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BTMD earnings forecast.

How were biote's earnings last quarter?: biote Corp. (NASDAQ:BTMD) released its quarterly earnings data on Tuesday, March, 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.06. The business had revenue of $45.70 million for the quarter, compared to analyst estimates of $45.50 million. biote had a negative trailing twelve-month return on equity of 45.10% and a net margin of 1.79%.
What guidance has biote issued on next quarter's earnings?: biote updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million.
Who are biote's major shareholders?: biote's stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (0.90%). Insiders that own company stock include Mary Elizabeth Conlon, Roystone Capital Management Lp and Samar Jagat Kamdar.
View institutional ownership trends.
How do I buy shares of biote?: Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTMD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial